COLORADO SPRINGS, Colo., Sept. 9, 2010 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTCBB:CBIS), a pioneering U.S. biotech company developing pharmaceutical cannabis products, is pleased with its progress with RockBrook Inc. as its first commercialization license for the Cannabis Science Brand of Pharmaceutical Products for the State of Colorado. The licensing agreement grants RockBrook the full latitude and rights to manufacture, develop, produce, distribute, and sell products developed from, or based on Cannabis Science formulations, and delivery systems for the Cannabis Science Brand of Pharmaceutical Products and Cannabis Science Ailment Formulations within the State of Colorado.
On August 30, 2010, FOX affiliate KTXL ("FOX40") aired one of the first paid U.S. television ads for a Cannabis Dispensary called CannaCare on its FOX40 Live morning news program. The 30-second ad focused on cannabis relief (treatment) for various medical ailments using true-life patient testimonials. Similarly, Cannabis Science is acquiring public testimonials using data acquired from RockBrook patients who use Cannabis Science Brands to evaluate our medical marijuana products prior to FDA clinical trials.
"It is a matter of record within the medical community that medical marijuana can have positive results in helping relieve nausea and vomiting among cancer patients receiving chemotherapy and increasing appetites among AIDS patients," Mike Armstrong, acting general manager of KTXL in Sacramento, said in a statement e-mailed to FOX40.com, alluding that the ad is no different from that of any medicine advertised by pharmaceutical companies on local television channels and cable networks for decades.
Cannabis Science President and CEO Dr. Robert Melamede, PhD., noted, "The FOX40 ad sets a new milestone for general public acceptance of medical cannabis. Centuries of knowledge record that cannabis is an efficacious medicinal treatment for a host of ailments, yet governments continues to cling to clouded ideologies against this natural medicine and instead support man-made pharmaceuticals that often produce more harm than medicinal good. We are optimistic that the unique holistic value of medical cannabis, with its ability to supplement our natural endocannabinoid system will continue to spread throughout the country and the world. Dispensaries currently lead the way throughout California and other U.S. states, such as Colorado where our licensed dispensary is located. The Company sees this as an opportune time to expand the marketing of its products and licensing dispensaries. We look forward to future TV marketing campaigns for Cannabis Science products and our licensed RockBrook dispensary."
Richard Cowan, Cannabis Science CFO, added, "We are encouraged that mainstream media is accepting medical cannabis dispensary advertisements in California, which is opening the door for us to expand the advertisement of our own licensed dispensary and products. On August 30, 2010, FOX affiliate KTXL ("FOX40") aired the first ever-paid U.S. television ad for a medical cannabis dispensary on its FOX40 Live morning news program. The 30-second ad focused on cannabis relief (treatment) for various medical ailments using true-life patient testimonials. From a marketing perspective, this is a huge leap forward in giving medical cannabis dispensaries the opportunities that chemically manufactured medicines have long held."
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
CONTACT: Cannabis Science, Inc. Dr. Robert J. Melamede, President & CEO 1-888-889-0888 Investor Relations Mark J. Friedman 1-877-431-CBIS (2247) firstname.lastname@example.org www.cannabisscience.com